Roche's Herceptin KO's tumors

Fast-growing tumors keel over in the face of Herceptin combined with chemotherapy--sometimes so completely that mastectomy wasn't necessary. Such are the late-stage study results that Roche proudly announced today. Tumors disappeared completely in 55 percent of the study patients, and from the breast and lymph nodes in 48 percent.

No specifics on side effects, just the standard assurance that treatment was "well tolerated," with an addendum that cardiac safety was "acceptable." We'll have to wait until the study wraps to find out more.

- see Roche's release on Herceptin

Related Articles:
Roche files for expanded use of Herceptin. Report
Genentech wins approval for new Herceptin indication. Report
Blocking enzyme effective in preventing breast cancer. Report
JCO warns on radiation, Herceptin. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.